Combination therapy of pegylated interferon alpha 2a and ruxolitinib in myelofibrosis: a case report

被引：0
|
作者：
Hindilerden, F. [1 ]
Demiriz, I. [1 ]
机构：
[1] SBU Bakirkoy Dr Sadi Konuk Egitim & Arastirma Has, Hematol Klin, Istanbul, Turkey
来源：
LEUKEMIA RESEARCH | 2019年 / 85卷
关键词：
D O I：
10.1016/S0145-2126(19)30319-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP-24
引用
收藏
页码：S48 / S48
页数：1
相关论文
共 50 条
  • [41] Long term results after therapy with pegylated interferon alpha 2a in HCV positive liver transplant recipients
    Bahra, M
    Neumann, UP
    Jacob, D
    Langrehr, JM
    Neuhaus, R
    Neuhaus, P
    HEPATOLOGY, 2005, 42 (04) : 488A - 489A
  • [42] Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report
    Gamal, Nesrine
    Brodosi, Lucia
    Misciali, Cosimo
    Patrizi, Annalisa
    Vukatana, Gentiana
    Malavolta, Nazzarena
    Bernardi, Mauro
    Andreone, Pietro
    ANNALS OF HEPATOLOGY, 2014, 13 (02) : 293 - 296
  • [43] Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib
    Bjorn, Mads Emil
    Hasselbalch, Hans Carl
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (05) : 393 - 404
  • [44] Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review
    Bucelli, Cristina
    Cattaneo, Daniele
    Valli, Viviana Beatrice
    Levati, Giorgia Virginia
    Lonati, Silvia
    Gianelli, Umberto
    Iurlo, Alessandra
    CHEMOTHERAPY, 2018, 63 (06) : 340 - 344
  • [45] Clinical and molecular response during pegylated interferon alpha therapy in primary and post-polycythemic myelofibrosis
    Gisslinger, H.
    Gisslinger, B.
    Griesshammer, M.
    Langer, C.
    Fiegl, M.
    Thaler, J.
    Schoder, R.
    Schauer, S.
    Muellauer, L.
    Simonitsch-Klupp, I.
    Kralovics, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 242 - 243
  • [46] Pegylated interferon-alpha induced sarcoidosis: report of a new case
    Xu Hui
    Shi Ruo-fei
    Zheng Jie
    JOURNAL OF DERMATOLOGY, 2012, 39 : 142 - 142
  • [47] Emerging strategies for pegylated interferon combination therapy
    Eugene R Schiff
    Nature Clinical Practice Gastroenterology & Hepatology, 2007, 4 : S17 - S21
  • [48] Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: A case report
    Jiang W.
    Hidaka H.
    Nakazawa T.
    Kitagawa H.
    Koizumi W.
    BMC Research Notes, 7 (1)
  • [49] Emerging strategies for pegylated interferon combination therapy
    Schiff, Eugene R.
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2007, 4 : S17 - S21
  • [50] Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib
    Frankel, Arthur E.
    Reddy, Renuka
    DeSuza, Kayla R.
    Deeb, Khaled
    Carlin, Aaron F.
    Smith, Davey
    Xie, Yushuang
    Naik, Eknath
    Silver, Richard T.
    Hasselbalch, Hans C.
    CLINICAL CASE REPORTS, 2021, 9 (04): : 2228 - 2235
12345